LCTX Lineage Cell Therapeutics Inc

Price (delayed)

$2.7

Market cap

$437.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$384.6M

Highlights
LCTX's EPS has soared by 78% year-on-year and by 36% since the previous quarter
The company's net income has surged by 77% YoY and by 34% QoQ
The gross profit has plunged by 51% YoY and by 10% from the previous quarter
The revenue has contracted by 45% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of LCTX
Market
Shares outstanding
162.14M
Market cap
$437.78M
Enterprise value
$384.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.71
Price to sales (P/S)
251.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
225.84
Earnings
Revenue
$1.7M
EBIT
-$14.91M
EBITDA
-$13.22M
Free cash flow
-$22.19M
Per share
EPS
-$0.09
Free cash flow per share
-$0.14
Book value per share
$0.73
Revenue per share
$0.01
TBVPS
$0.44
Balance sheet
Total assets
$127.93M
Total liabilities
$11.36M
Debt
$3.03M
Equity
$117.67M
Working capital
$58M
Liquidity
Debt to equity
0.03
Current ratio
9.76
Quick ratio
9.44
Net debt/EBITDA
4.02
Margins
EBITDA margin
-776.1%
Gross margin
76.3%
Net margin
-802.5%
Operating margin
-1,530.2%
Efficiency
Return on assets
-12.1%
Return on equity
-13.5%
Return on invested capital
-86%
Return on capital employed
-12.3%
Return on sales
-875.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LCTX stock price

How has the Lineage Cell Therapeutics stock price performed over time
Intraday
-4.93%
1 week
-5.92%
1 month
17.9%
1 year
162.14%
YTD
53.41%
QTD
14.89%

Financial performance

How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$1.7M
Gross profit
$1.3M
Operating income
-$26.06M
Net income
-$13.67M
Gross margin
76.3%
Net margin
-802.5%
The company's net income has surged by 77% YoY and by 34% QoQ
The net margin has soared by 58% YoY and by 29% from the previous quarter
The gross profit has plunged by 51% YoY and by 10% from the previous quarter
The revenue has contracted by 45% YoY and by 7% from the previous quarter

Growth

What is Lineage Cell Therapeutics's growth rate over time

Valuation

What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
3.71
P/S
251.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
225.84
LCTX's EPS has soared by 78% year-on-year and by 36% since the previous quarter
LCTX's P/B is 86% above its 5-year quarterly average of 2.0 and 69% above its last 4 quarters average of 2.2
LCTX's equity is up by 22% QoQ and by 10% YoY
LCTX's price to sales (P/S) is 117% more than its last 4 quarters average of 115.9
The revenue has contracted by 45% YoY and by 7% from the previous quarter

Efficiency

How efficient is Lineage Cell Therapeutics business performance
LCTX's return on equity has surged by 73% year-on-year and by 36% since the previous quarter
Lineage Cell Therapeutics's ROA has soared by 73% YoY and by 35% from the previous quarter
LCTX's ROS has soared by 57% year-on-year and by 27% since the previous quarter
Lineage Cell Therapeutics's ROIC has increased by 18% YoY but it has decreased by 5% from the previous quarter

Dividends

What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LCTX.

Financial health

How did Lineage Cell Therapeutics financials performed over time
Lineage Cell Therapeutics's quick ratio has surged by 76% QoQ and by 31% YoY
The current ratio has surged by 72% since the previous quarter and by 30% year-on-year
The debt is 97% less than the equity
The debt to equity has contracted by 40% YoY
The debt has contracted by 37% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.